Ardelyx, Inc. (ARDX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with ARDX?
Powered by Yahoo ScoutArdelyx delivered Q3 2026 product revenue of $125.5 million, driven by continued IBSRELA growth and higher XPHOZAH prescriptions. The company reaffirmed 2026 revenue guidance, completed ACCEL trial enrollment early, and maintained a target for commercial profitability in 2027. Reimbursement execution, XPHOZAH channel timing, and clinical outcomes remain the central variables.
- Previous Close
2.9900 - Open
2.9900 - Bid 3.6200 x 200
- Ask 6.4500 x 200
- Day's Range
2.8400 - 2.9900 - 52 Week Range
2.8400 - 8.4000 - Volume
5,441,741 - Avg. Volume
4,559,545 - Market Cap (intraday)
723.953M - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2300 - Earnings Date Nov 3, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
12.80 - Zacks Rating Neutral
Recent News
View MorePerformance Overview
Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (current)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-11.85%
-
Return on Assets (ttm)
-4.20%
-
Return on Equity (ttm)
-34.85%
-
Revenue (ttm)
468.22M
-
Net Income Avi to Common (ttm)
-55.47M
-
Diluted EPS (ttm)
-0.2300
Balance Sheet and Cash Flow
-
Total Cash (mrq)
285.34M
-
Total Debt/Equity (mrq)
172.85%
-
Levered Free Cash Flow (ttm)
33.02M
